Successful cases of treatment of Bevacizumab for preventing scar after trabeculectomy in glaucoma patients encourage us to explore its mechanism. In this study, we primarily isolated conjunctival fibroblast from rat. RT-PCR analysis for the cells implicated that conjunctival fibroblast expressed vascular endothelial growth factor (VEGF) and its receptors. Immunofluorescence staining also showed positive staining for VEGFR-1. Furthermore, growth of fibroblast was significantly inhibited by Bevacizumab at dose of 2.5 mg/ml. Real time PCR results showed after 48 h intervention of 2.5 mg/ml Bevacizumab, the mRNA expressions of VEGF and its receptors decreased compared to the control group (P < 0.05) and Bevacizumab also decreased expression of TGFβ1 and TGFβ2 (P < 0.05). In summary, our finding demonstrated that Bevacizumab could directly act on fibroblast and inhibit VEGF, TGFβ1, and TGFβ2 expression.
Keywords: Bevacizumab; Conjunctival fibroblast; TGFβ1; TGFβ2; VEGF.